Basil M. Hantash, MD, PhD
 Dr. Hantash is a 16-year veteran of
regenerative medicine, conducting pioneering research at Stanford
University investigating the mechanisms underlying mesenchymal stem
cell immune tolerance. Dr. Hantash has founded and served on the
executive management team of several regenerative medicine companies.
He has over 9 years of operational experience in the life sciences and
has been an active member of the board of directors and Scientific Advisory Board of numerous medtech, biotech, and aesthetic medicine
companies. His track record includes the successful launch of over a
dozen life sciences products across multiple disciplines including
diagnostics, small molecule drugs, medical devices, biomaterials,
nanotechnology, cosmeceuticals, and nutraceuticals. Dr. Hantash has
been intimately involved in all aspects of the start-up process,
helping secure financing and providing guidance on technology,
regulatory, intellectual property, and business development strategies.Dr. Hantash completed his dermatology residency, postdoctoral training in the Program for Regenerative Medicine, and a prestigious fellowship in the Biodesign Innovation Program at Stanford University. He received his MD and PhD (pharmacology and physiology) from New Jersey Medical School, where he was inducted in the AOA Medical Honor Society and graduated as valedictorian of both his Graduate and Medical School. Dr. Hantash received his BS in Biology and minor in Chemistry from the University of Illinois, where he was the recipient of a Howard Hughes Research Fellowship. Dr. Hantash has performed over a dozen clinical trials, has 22 patents pending, and has published over 65 scientific peer-reviewed articles, abstracts, and chapters. He remains intimately involved in humanitarian relief work and is an award-winning poet featured in several books and one audio CD. |